Sat, Sep 20, 2014, 3:04 AM EDT - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

Apollo Education Group, Inc. Message Board

vermaatul1 43 posts  |  Last Activity: Sep 16, 2014 8:50 PM Member since: Apr 20, 2012
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • vermaatul1 by vermaatul1 Jul 8, 2014 9:52 PM Flag

    July 8, 2014 | By Meaghan Molloy | Threat Intelligence, Threat Research |
    Coordinated botnet disruptions have increased in pace and popularity over the last few years as more private companies work with international law enforcement agencies to combat malware infections on a grand scale. Operation Tovar, announced on June 2 2014, is the latest to make headlines. The target of the investigation, Evgeniy Mikhailovich Bogachev, was indicted by the Department of Justice and is wanted by the FBI for his role as alleged leader of the Gameover ZeuS and CryptoLocker botnets. Four other defendants were indicted using their pseudonyms. Though Bogachev’s current activities aren’t known, the Operation Tovar task force has maintained control of the botnet infrastructure and remediation efforts are ongoing.

    While new malware strains are released with increasing frequency, it’s easy to forget why Gameover and CryptoLocker are worthwhile targets for takedown operations. Both offered more advanced features than their peers and typified the increasingly sophisticated cybercriminal enterprises behind botnets.

    Gameover ZeuS

    Since the ZeuS source code was released in 2011, several new variants have appeared in the wild. Citadel, KINS, ICE IX, and Gameover have all improved upon the basic ZeuS model by introducing new features, using better encryption, and modifying command and control (C2) communication methods.

    Gameover uses a peer-to-peer (P2P) system for C2 communication. Though other P2P botnets such as Kelihos exist, Gameover is notable for its use of proxy nodes to introduce complexity into the standard P2P infrastructure. These proxy nodes are specific machines designated as relay points through which the botnet operators send commands and receive stolen information. This minimizes the number of systems that actually communicate with C2 servers. C2 commands are signed using RSA-2048 and encrypted with RC4 making it very difficult to tamper with the

    Sentiment: Strong Buy

  • Some one accumulated big amount within last 2 days. The next stop is 57.40. If you short better you cover. its a bull market. All short sellers will get killed. Tomorrow SINA will close $3.50 or higher from today closing price. You need to watch the chart.

    Sentiment: Strong Buy

  • Due to increase demand of security software worldwide. You will see FEYE value within 2 weeks. Shorts are too greedy trying to keep it down. AMZN don't make any money either but traded at $325 why not FEYE.

    Sentiment: Strong Buy

  • From FEYE website-blog. A new product by FEYE.

  • FBI Supervisory Special Agent J. Keith Mularski, answers questions about the May 19, 2014 indictment against five Chinese military officials charged with economic espionage and trade secret theft during a news conference at the FBI offices in Pittsburgh on Tuesday, May 20, 2014. (AP Photo/Keith Srakocic)
    PITTSBURGH (AP) — J. Keith Mularski's world has expanded greatly since he stopped selling discount furniture to join the FBI in 1998. Especially since he transferred from Washington, D.C., in 2005 to fill a vacancy in the Pittsburgh field office's cyber squad — which he now heaSince then, Supervisory Special Agent Mularski has been recognized as a foremost expert on cybercrime. His profile has risen even more since the Justice Department used Mularski's sleuthing to bring two indictments with worldwide ramifications.

    In May, five Chinese Army intelligence officers were charged with stealing trade secrets from major manufacturers including U.S. Steel, Alcoa and Westinghouse.

    In June, a Russian man was charged with leading a ring that infected hundreds of thousands of computers with identity-thieving software, then using the stolen information to drain $100 million from bank accounts worldwide.

    Mularski, 44, said in April during an oral history interview for the National Law Enforcement Museum that he became a furniture salesman out of college because jobs were hard to come by then. He spent about five years in the business before joining the FBI.

    "I was in private industry beforehand. But I've kind of always liked computers," Mularski told The Associated Press during a recent interview.

    All 56 FBI field offices have cyber squads. Mularski chose Pittsburgh largely because of family considerations — he grew up in suburban White Oak, the son of a steelworker.

    "It kind of looked like cyber was the wave of the future," Mularski said. "The majority of all my computer training was just on-the-job training at the bureau."

    It has proved remarkabl

  • Yahoo finance from SA

    Sentiment: Strong Buy

  • Watch the live show tomorrow & expect at least $2-3 upside. Corrupt us market controlled by hedgier they brought FEYE down from $42-$33.50 within less than a week now they accumulated big amount. It’s time to move back again $50 before earning. If you don't belief me watch the chart from today at least 10 support point at $33.66. All accumulation occurs between $33.66-33.80. Same things happen with MYL a few months ago when stock was trading at $ 32 and compare today price around $51. I am long and planning to hold until its go back to $97 due to I know the value of security stocks. If you sell at this price, you fooled by manipulators..

    Sentiment: Strong Buy

  • Zerenex(TM) (ferric citrate), is an oral, ferric iron-based phosphate binder. Keryx has completed a U.S.-based phase 3 clinical program for Zerenex for the treatment of hyperphosphatemia (elevated phosphate levels) in ESRD patients on dialysis, conducted pursuant to a Special Protocol Assessment (SPA) agreement with the FDA. To date, over 1,500 CKD patients have been exposed to Zerenex through completed phase 2 and 3 clinical trials. The Company's New Drug Application (NDA) is currently under review by the FDA with an assigned Prescription Drug User Fee Act (PDUFA) goal date of September 7, 2014. Keryx has filed a Marketing Authorization Application (MAA) with the European Medicines Agency (EMA), seeking the approval of Zerenex as a treatment of hyperphosphatemia in patients with all stages of CKD and that application is currently under review.

    Sentiment: Strong Buy

  • From Benzinga

    Sentiment: Strong Buy

  • Twitter Inc (NYSE:TWTR) stock may be starting to settle down after the shock that was the company’s earnings report earlier this week. Analysts from multiple firms have been increasing their estimates and / or upgrading Twitter stock in the wake of that report. This time FBN Securities analyst Shebly Seyrafi upgraded Twitter from Sector Perform to Outperform and increased their price target from $50 to $60

    Sentiment: Strong Buy

  • due to its not moving. FEYE is a Jock and controlled by short sellers. I joined their gang..

    Sentiment: Hold

  • Reply to


    by joe_the_dumber Aug 6, 2014 8:24 PM
    vermaatul1 vermaatul1 Aug 6, 2014 8:52 PM Flag

    Compare Chipotle at $675 and LOCO at $37.00. Where is your brain? Its a common sense that's why all we are buying until it goes $50.00

    Sentiment: Strong Buy

  • Reply to

    How many morons purchased above $40?

    by newlchinascam Aug 6, 2014 9:36 PM
    vermaatul1 vermaatul1 Aug 6, 2014 9:54 PM Flag

    Why don't you short Chipotle or GMCR instead LOCO. Are you crazy? LOCO will go to $60 easy.

    Sentiment: Strong Buy

  • Reply to

    How many morons purchased above $40?

    by newlchinascam Aug 6, 2014 9:36 PM
    vermaatul1 vermaatul1 Aug 6, 2014 10:39 PM Flag

    LOCO is also a hedge fund favorites that's why stock doubled in 2 days from IPO price. Don't go against the trend or you will loose more.

    Sentiment: Strong Buy

  • vermaatul1 vermaatul1 Aug 6, 2014 10:43 PM Flag

    I think you are spending your time and money on wrong stock. No one going to listen you so better find some other stocks to short like FEYE, PNRA,GMCR,TSLA.

    Sentiment: Strong Buy

  • vermaatul1 by vermaatul1 Aug 12, 2014 11:30 AM Flag

    New CEO is alexsimonelis. Now stock will fly to $55

    Sentiment: Strong Buy

  • GENEVA — West Africa’s deadly Ebola epidemic is probably much worse than the world realizes, with health centers on the front lines warning that the actual numbers of deaths and illnesses are significantly higher than the official estimates, the World Health Organization said.
    So far, 2,127 cases of the disease and 1,145 deaths have been reported in four nations — Guinea, Liberia, Nigeria and Sierra Leone — the W.H.O announced Friday. But the organization has also warned that the actual number is almost certainly higher, perhaps by a very considerable margin.
    “Staff at the outbreak sites see evidence that the numbers of reported cases and deaths vastly underestimate the magnitude of the outbreak,” the group said in a statement on Thursday.
    Continue reading the main story

    Hospitals in the U.S. Get Ready for Ebola AUG. 15, 2014

    A government burial team in Sierra Leone. As Ebola claims more victims, false cures are being marketed toward Africans.

    Agencies Issue Warnings Over Bogus Ebola Cures AUG. 15, 2014

    An Ebola isolation ward in Monrovia, Liberia. Nigeria hopes to wipe out the disease before it spirals out of control, as it has in Liberia, Guinea and Sierra Leone.

    With Ebola Cases Still Few, Populous Nigeria Has Chance to Halt Its Outbreak AUG. 15, 2014

    A warning in Ivory Coast. The illness has appeared in Liberia, Sierra Leone, Guinea and Nigeria.

    Health Officials Try to Quell Fear of Ebola Spreading by Air Travel AUG. 14, 2014
    Times Topic: The Ebola Outbreak in West Africa
    The epidemic is still growing faster than efforts to keep up with it, and it will take months before governments and health workers in the region can get the upper hand, Joanne Liu, the president of Doctors Without Borders, said on Friday, calling conditions on the ground “like a war.”

  • Google it. from 08/17/2014 9 am.

  • Because they are under fire. I am planning to open new position tomorrow am. I am in medical field and I know the value of no tube in the rectum after 50 years so you don't want either too. I promise everyone will like this non invasive test. Global demand for this test is much higher than investors think today. See you after a month on this board with new high

    Sentiment: Strong Buy

  • Experimental Drug Used for Ebola-Related Virus Shows Promise

    By ANDREW POLLACKAUG. 20, 2014

    An experimental drug has completely protected monkeys from lethal doses of a virus related to Ebola, bolstering confidence that a similar medicine might be effective if deployed in the current outbreak in Africa, researchers reported on Wednesday.

    The researchers said that the drug, which is being developed by Tekmira Pharmaceuticals, kept all monkeys alive in a study, even if given as late as three days after exposure to the Marburg virus, when the virus was already detectable in the animals’ blood.

    Both Marburg and Ebola are filoviruses that cause deadly hemorrhagic fever characterized by vomiting, diarrhea, uncontrolled bleeding and possible organ failure. Tekmira, which is based in British Columbia, has a separate drug for Ebola that is already in early testing in healthy human volunteers. Both drugs work the same way — turning off viral genes through an approach called RNA interference.

    Continue reading the main story

    Related Coverage

    A Reynolds American plant in Owensboro, Ky., makes ZMapp inside the leaves of tobacco plants, but production is very limited.

    Ebola Therapy From an Obscure Biotech Firm Is Hurried AlongAUG. 6, 2014

    “It is very important to not give false hope to anybody that Ebola can be treated now,” said Dr. Marie-Paule Kieny at a news conference in Geneva.

    As Ebola’s Toll Rises, Drug Makers Race to Test MedicinesAUG. 13, 2014

    Second Drug Is Allowed for Treatment of EbolaAUG. 7, 2014

    Workers moving an Ebola victim’s body. The outbreak was called a global health emergency Friday.

    Ebola Drug Could Save a Few Lives. But Whose?AUG. 8, 2014

    Marburg virus was first described in 1967 after outbreaks in three European cities, including Marburg, Germany, caused by the importation of monkeys from Uganda. The biggest outbreak was in Angola in 2004 and 2005, which affected m
    Tekmira’s Marburg drug moves in that direction. The virus was detectable in the monkey’s blood three days after exposure, corresponding to the time an infection might first be diagnosed using a test.

    The study demonstrates the “real-world utility of this technology,” said Dr. Thomas W. Geisbert, a professor of microbiology and immunology at the University of Texas Medical Branch at Galveston and a senior author of the study, which is being published in Science Translational Medicine. He said more studies were being planned to determine whether the drug could be used even later.

    Dr. Daniel G. Bausch, an associate professor of tropical medicine at Tulane University, who was not involved in the study, said effectiveness at three days postexposure was not that useful. In an outbreak, only people who are closely monitored — such as those who have had contact with an infected person — might get a diagnosis based on a blood test, before symptoms appear.

    “The vast majority of people come in after they are sick for a couple of days,” Dr. Bausch said. In the study, even the monkeys that did not get the drug did not show symptoms until about six days after exposure.

    In the study, paid for by the National Institutes of Health, 21 rhesus macaques were injected with a high dose of the Angola strain of Marburg, the most lethal strain, with a human fatality rate of up to 90 percent.

    The monkeys were given daily injections of the drug for seven days. For four of the monkeys, the injections did not start until 72 hours after exposure. The others began receiving the drug at earlier time points.

    Continue reading the main story Continue reading the main story

    All 16 of the treated animals survived, with reduced viral levels and disease symptoms. The five monkeys in the control group all died or became so sick they were euthanized.

    The study was paid for by the National Institutes of Health. Some authors work for Tekmira, and Dr. Geisbert has patent rights to this type of treatment.

    Gene G. Olinger, an Ebola and Marburg expert at MRIGlobal, a research institute, said other experimental drugs had provided protection at three days or later, but usually not 100 percent.

    Two-thirds of monkeys given Tekmira’s Ebola drug three days after exposure survived. A predecessor of ZMapp, a drug that appears to have helped two American aid workers stricken with Ebola, three of seven monkeys lived when given the drug four to five days after exposure to Ebola, when some of the animals had symptoms.

    Tekmira executives have said the company was evaluating possible ways to use its Ebola drug in the current outbreak, but they have provided little detail. An executive said last week that it would take months to make more of the drug, which is being developed under a Defense Department contract.

    The Food and Drug Administration halted testing of the Ebola drug in healthy volunteers last month after some patients suffered inflammatory reactions at high doses. This month, however, the F.D.A. said the drug could be tested on people who were actually infected.

    RNA interference, the technique used by Tekmira, is a way to turn off potentially any gene. It holds promise for treating many diseases, not just viral infections.

    Such drugs typically consist of short stretches of synthesized double-stranded RNA that match part of the gene to be silenced. The challenge for drug companies has been delivering the RNA through the bloodstream and into the cells where it is needed. Tekmira encapsulates the RNA in microscopic lipid particles to help in this.

    “This technique of getting a lipid-encapsulated product that can actually enter the cell efficiently is something that is important,” said Dr. Anthony S. Fauci, director of the National Institute of Allergy and Infectious Diseas

    Sentiment: Strong Buy

26.08-0.51(-1.92%)Sep 19 4:00 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
TC PipeLines, LP
NYSEFri, Sep 19, 2014 4:00 PM EDT
Oracle Corporation
NYSEFri, Sep 19, 2014 4:00 PM EDT